See at minute 41:20: Ivermectin meta-analysis by Dr. Andrew Hill EXTENDED

00:01 Opening comments and background of Dr. Andrew Hill
1:15 Discussion of repurposing drugs for COVID-19, and a summary of the progress made to date.
3:40 Background on ivermectin including the cost of treatment in different countries along with the cost of production
6:25 Overview of the systematic review and meta-analysis of ivermectin completed by Dr. Andrew Hill.
8:10 Overview of the scope of the current meta-analysis: 18 randomized trials across 11 countries with 2200+ patients. Brief overview of other ivermectin randomized trials in progress.
9:10 Overview of 9 randomized trials in 1125 patients with mostly mild to moderate COVID-19 illness given a single dose on Day 1
10:30 Overview of 9 other randomized trials in 1119 patients with mostly mild to moderate COVID-19 illness with multi-day dosing
12:10 Discussion of the methods used and primary end points in the meta-analysis.
13:15 Discussion of the methods used to assess quality of each randomized clinical trial
15:00 Results of the ivermectin meta-analysis:
15:15 Effects of on inflammatory markers
17:05 Effects on viral clearance with a single day of treatment
19:00 Effects of different single-day doses on viral clearance
20:50 Effects on viral clearance with multi-day dosing
22:55 Effects on clinical recovery and hospitalization:
23:15 Effects of a single day of treatment on clinical recovery and hospitalization
23:45 Effects of multi-day dosing on hospitalization or clinical recovery
24:15 Effects of ivermectin on survival—results from six studies
26:00 Discussion of the limitations of the studies included in the meta-analysis
27:40 Cochrane risk of bias assessment
29:05 Implications: ivermectin treatment as prevention
30:15 Review of 3 randomized trials of ivermectin for prevention
30:40 Conclusions
32:35 Overview of trial data emerging in Feb through April 2020
34:40 Dr. Hill’s personal opinion on when to approve ivermectin--the dilemma of early vs late approval decisions
37:45 Q&A:
37:50 Q: When will meta-analysis data be released?
38:15 Q: Would you recommend a family member in hospital with COVID-19 for a placebo controlled trial of ivermectin?
39:00 Q: In a court of law, would you be able to claim that ivermectin was clinically effective?
39:40 Q: What about co-treatment with other drugs in the trials?
40:10 Q: Could ivermectin affect immunity post-COVID?
40:20 Q: Does ivermectin have an effect on hospitalization?
40:45 Q: Are there other factors such as dosage which could affect efficacy?
41:20 Q: Can these data be used to accelerate the acceptance of ivermectin as a treatment for COVID-19?
41:40 Q: What importance is placed on observational studies and unpublished studies?
43:10 Q: Methodological issues with the Elgazzar trial—why did you include?
43:30 Q: What can we learn from other re-purposed drugs in terms of bias?

source:
https://www.youtube.com/watch?v=eu61dtsSLrk